Piotr Swat / Shutterstock.com
The US Federal Trade Commission (FTC) concluded a ten-year pay-for-delay suit yesterday, with AbbVie agreeing not to enter certain settlements in patent cases that delay market entry of generic drugs.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
US Federal Trade Commission, FTC, pharmaceuticals, pay-for-delay, US Supreme Court, settlement, Actavis, AbbVie, generics, reverse payments, AndroGel